We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
+7.33%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.44B
AUM Growth
+$259M
(+4.2%)
Cap. Flow
+$405M
Cap. Flow
% of AUM
6.29%
Top 10 Holdings %
Top 10 Hldgs %
34.31%
Holding
1,318
New
461
Increased
339
Reduced
236
Closed
232
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$330M |
| 2 |
Brookdale Senior Living
BKD
|
+$93.7M |
| 3 |
Tenet Healthcare
THC
|
+$85.2M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$70.6M |
| 5 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$64.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$206M |
| 2 |
CVS Health
CVS
|
+$122M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$102M |
| 4 |
McKesson
MCK
|
+$80.6M |
| 5 |
Pacira BioSciences
PCRX
|
+$45.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.63% |
| 2 | Energy | 5.88% |
| 3 | Consumer Discretionary | 5.63% |
| 4 | Financials | 4.88% |
| 5 | Industrials | 3.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $430M | 6.68% |
1,926,842
-216,721
| -10% | -$44.9M |
|
|
AGN
2
DELISTED
Allergan Inc
AGN
| $409M | 6.36% |
2,416,852
+2,120,293
| +715% | +$330M |
|
|
ENDP
3
DELISTED
Endo International plc
ENDP
| $322M | 5% |
4,598,007
+1,055,233
| +30% | +$70.6M |
|
|
4
Brookdale Senior Living
BKD
$3.57B
| $285M | 4.43% |
8,543,694
+2,882,594
| +51% | +$93.7M |
|
|
SLXP
5
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $224M | 3.48% |
1,814,999
+50,433
| +3% | +$5.57M |
|
6
Cardinal Health
CAH
$54.5B
| $205M | 3.18% |
2,983,777
-207,570
| -7% | -$14.1M |
|
|
7
Tenet Healthcare
THC
$22.4B
| $106M | 1.65% |
2,264,177
+1,885,393
| +498% | +$85.2M |
|
|
COV
8
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $86.9M | 1.35% |
963,508
+859,308
| +825% | +$64.3M |
|
9
MetLife
MET
$62.4B
| $73.5M | 1.14% |
1,483,322
+6,162
| +0.4% | +$288K |
|
|
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
| $67.4M | 1.05% |
2,145,180
+681,538
| +47% | +$20.4M |
|
11
Healthcare Realty
HR
$7.56B
| $55.8M | 0.87% |
2,317,809
+376,519
| +19% | +$8.97M |
|
12
Patterson-UTI
PTEN
$3.56B
| $54.6M | 0.85% |
1,564,106
+706,583
| +82% | +$23.2M |
|
|
GRFS
13
Grifois
GRFS
$5.55B
| $51M | 0.79% |
2,313,946
-274,812
| -11% | -$5.75M |
|
14
Regeneron Pharmaceuticals
REGN
$73.1B
| $50.8M | 0.79% |
179,728
-106,835
| -37% | -$31.7M |
|
15
Liberty Media Series A
FWONA
$23.3B
| $48.9M | 0.76% |
2,012,638
+762,675
| +61% | +$17.5M |
|
|
16
McKesson
MCK
$106B
| $48.2M | 0.75% |
258,851
-452,842
| -64% | -$80.6M |
|
|
SPNC
17
DELISTED
Spectranetics Corp
SPNC
| $45.4M | 0.71% |
1,984,900
+1,464,900
| +282% | +$34M |
|
|
AMRI
18
DELISTED
Albany Molecular Research Inc
AMRI
| $43.7M | 0.68% |
2,170,000
-980,000
| -31% | -$16.6M |
|
|
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
| $42.9M | 0.67% |
2,070,870
+70,670
| +4% | +$1.31M |
|
20
HCA Healthcare
HCA
$92.2B
| $42M | 0.65% |
744,257
+170,928
| +30% | +$9.02M |
|
21
Medifast
MED
$107M
| $41.1M | 0.64% |
1,350,000
| – | – |
|
|
LVNTA
22
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
| $40.8M | 0.63% |
1,125,272
+184,772
| +20% | +$5.81M |
|
|
23
Pacira BioSciences
PCRX
$1.04B
| $40.3M | 0.63% |
438,318
-591,682
| -57% | -$45.1M |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $39M | 0.61% |
2,466,063
+228,063
| +10% | +$3.26M |
|
25
Canadian Natural Resources
CNQ
$96.4B
| $37.2M | 0.58% |
1,668,609
+647,300
| +63% | +$12.9M |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Visium Asset Management held 1,318 positions worth $6.44B, up 4.2% from $6.18B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Visium Asset Management deployed $405M of net new capital in Q2 2014, opening 461 new positions and adding to 339 existing holdings. Its largest new stake was NPS PHARMACEUTICALS INC: 1,020,622 shares worth $33.7M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 53% a quarter earlier, followed by Energy and Consumer Discretionary.
On the sell side, the largest reduction was Bausch Health, an estimated $206M trimmed.
- Visium Asset Management's largest Q2 2014 buy was NPS PHARMACEUTICALS INC: 1,020,622 shares worth $33.7M.
- Visium Asset Management added most to Allergan Inc in Q2 2014, an estimated $330M increase.
- Visium Asset Management's biggest Q2 2014 reduction was Bausch Health, cutting an estimated $206M.
- Visium Asset Management fully exited QUESTCOR PHARMA INC in Q2 2014, selling an estimated $34M.
- Visium Asset Management's ten largest holdings make up 34% of its $6.44B portfolio in Q2 2014.
- Visium Asset Management opened 461 new positions and closed 232 in Q2 2014.
- Visium Asset Management's portfolio value rose 4.2% quarter-over-quarter to $6.44B.
Based on Visium Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.